Evaluating nursery pig responses to in-feed sub-therapeutic antibiotics

Emma T. Helm¹, Shelby Curry², Julian M. Trachsel³, Martine Schroyen⁴, Nicholas K. Gabler¹*¹

¹ Department of Animal Science, Iowa State University, Ames, Iowa, United States of America, ² Oak Ridge Institute for Science and Education, Oak Ridge, Tennessee, United States of America, ³ Food Safety and Enteric Pathogens Research Unit, National Animal Disease Center, Agriculture Research Service, United States Department of Agriculture, Ames, Iowa, United States of America, ⁴ Precision Livestock and Nutrition Unit, TERRA Teaching and Research centre, Gembloux Agro-Bio Tech, University of Liège, Gembloux, Belgium

* ngabler@iastate.edu

Abstract

Antibiotics have been used for over 60 years by the swine industry to improve growth performance and feed efficiency. With rising concerns over antimicrobial resistance and government restrictions such as the Veterinary Feed Directive on usage of in-feed antibiotics, alternatives to feeding antibiotic growth promoters (AGPs) to nursery pigs are needed. However, the mechanism of action by which AGPs work is poorly understood. Thus, the objective of this study was to investigate the mechanisms of action by which AGPs increase nursery pig performance. Over two replicates, 24 weaned pigs (6.75 ± 0.75 kg body weight) were randomly allotted to either control (CON, n = 12) or sub-therapeutic antibiotic (sCTC, n = 12) treatments and housed individually. A 2-phase corn-soybean-based nursery diet was fed, with the sCTC diets containing 40 ppm feed-grade chlortetracycline. Individual pig average daily gain (ADG), average daily feed intake (ADFI), and gain to feed ratio (G:F) were calculated weekly for 5 weeks. Thereafter, all pigs were euthanized and necropsied for tissue collection. The overall performance data indicated that sCTC pigs had increased ADG (0.43 vs. 0.32 kg/d, \( P = 0.001 \)) and ADFI (0.51 vs. 0.37 kg/d, \( P = 0.002 \)) compared with CON pigs; however, G:F was not different as a result of dietary treatment (0.85 vs. 0.88, \( P = 0.617 \)). Intestinal barrier permeability, ileal active nutrient transport, and cecal short chain fatty acid concentrations did not differ (\( P > 0.10 \)) due to dietary treatment, however changes in several ileum mRNA transcripts suggest that inflammation may be reduced in sCTC pigs. Further, the changes observed in the proteomes of the ileum, colon, skeletal muscle, and liver suggest that the sub-therapeutic mode of action of AGPs may include post-absorptive changes and warrants further investigation.

Introduction

Sub-therapeutic antibiotic growth promotants (AGPs) have been used heavily by the swine industry since their growth promoting qualities were first discovered in the 1940s [1]. Antibiotic growth promotants have been shown to consistently improve body weight gain and feed...
efficiency in growing pigs, specifically during the nursery phase [2]. However, rising concerns over antimicrobial resistance to antibiotics has resulted in the United States animal agriculture sector banning the use of sub-therapeutic growth promoting antibiotics via the recent implementation of the 2017 Veterinary Feed Directive (VFD) [3]. The VFD prohibits the usage of sub-therapeutic AGPs, which can be defined an antimicrobial fed at concentrations lower than the lowest concentration that will inhibit the growth of the target microorganism of that antimicrobial. One of the most commonly used AGPs has been chlortetracycline (CTC) [4]. The potential of tetracycline antibiotics to promote growth was first shown in the 1940s when healthy animals that consumed dried mycelia of Streptomyces aureofaciens containing chlortetracycline residues were observed to have improved growth [5]. The tetracycline class of antibiotics exert their effect on Gram-positive, and to a lesser extent, Gram-negative bacteria by binding to the bacterial 30S and 50S ribosome and halting protein synthesis [6, 7]. In hosts, tetracyclines have also been shown to act as reactive oxygen species scavengers or anti-inflammatory agents, to inhibit matrix metalloproteinases, and to possess anti-apoptotic properties [6]. Tetracycline antibiotics have been used both therapeutically and sub-therapeutically in animal agriculture. In-feed therapeutic levels of CTC have historically been 400 ppm or greater [8]. For use as an in-feed sub-therapeutic AGP, CTC has been added at low concentrations (2.5 ppm to 125 ppm), depending upon both the animal species and the drug type, to enhance animal performance as opposed to treating, controlling, and preventing disease [9, 10].

The loss of a major production tool has created a need by animal production industries to find alternatives that mimic the beneficial performance aspect of AGPs while minimizing the potential for antibiotic resistance. Despite their heavy usage in the livestock industry, the mechanism by which AGPs increase growth performance is still largely unknown. The hypothesis that has received the most attention proposes that AGPs act indirectly on the pig via modulation of the intestinal microbiota. This hypothesis suggests that AGPs reduce production of growth-depressing metabolites by microbes, suppress pathogenic microbial growth, and reduce competition for nutrients to allow for heightened nutrient uptake [11]. The hypothesis is best supported by the observation that antibiotics don’t improve the growth of germfree chicks [12]; however, a clear and direct link between AGPs and modulation of the intestinal microbiota has not yet been demonstrated [9].

Another hypothesis postulates that AGPs act via a more direct effect on the host. This hypothesis primarily revolves around immunomodulation of the gastrointestinal tract (GIT), in which AGPs exert anti-inflammatory properties on the intestine, resulting in more energy being available for lean tissue growth rather than maintaining an immune response [13]. Although studies investigating the immunomodulatory hypothesis are limited, Costa et al. [13] demonstrated that sub-therapeutic levels of CTC altered the immune response to Citrobacter rodentium infection in mice, consistent with the immunomodulatory hypothesis.

In order to develop better in-feed technologies to replace AGPs such as CTC, one must first understand how they act on the host to improve growth. Therefore, the aim of this study was to examine the mechanism(s) by which in-feed sub-therapeutic CTC enhances the growth performance of nursery pigs. A whole body, shotgun proteomic and PCR array approach was utilized to identify potential mechanisms of action by which CTC improves growth performance of nursery pigs.

Materials and methods

All animal procedures in this study were approved by the Iowa State University Institutional Animal Care and Use Committee (protocol number 4-16-8251-S) and adhered to the ethical and humane use of animals for research.
Animals, housing, and experimental design

This experiment was performed in two experimental replicates in the summer and autumn of 2016. A total of 24 weaned female pigs (Genetiporc 6.0 × Genetiporc F25; PIC, Inc., Hendersonville, TN), 19–21 days of age (6.75 ± 0.75 kg body weight), were randomly selected for this experiment. Pigs were vaccinated for PCV2 prior to weaning. After selection, pigs were randomly allotted to individual pens and assigned to one of two dietary treatments: 1) negative control group (CON, n = 12 pigs/trt), and 2) sub-therapeutic antibiotic treatment (sCTC, n = 12 pigs/trt). The sCTC treatment consisted of the basal CON diet mixed with feed-grade CTC (Zoetis, Parsippany, NJ) to achieve a final sub-therapeutic level of 40 ppm in feed. This sub-therapeutic concentration was chosen as it was the manufacturer’s recommended inclusion rate for growth promotion. Both treatment diets (Table 1) were fed as a two phase nursery mash diet formulated to meet all requirements for this size pig [14]. The phase 1 diet was fed from days 0–14 of the experiment, and the phase 2 diet was fed from days 14–35 of the experiment. Pigs were allowed free access to water and were ad libitum fed for the duration of the experiment.

On days 0, 7, 14, 21, 28, and 35 post-weaning, individual pig body weight and feed disappearance were recorded to calculate average daily gain (ADG), average daily feed intake (ADFI) and gain:feed (G:F) ratio. At day 35, 6 pigs per treatment were euthanized via captive

| Ingredient, % | CON Phase 1 | CON Phase 2 | sCTC Phase 1 | sCTC Phase 2 |
|---------------|-------------|-------------|--------------|--------------|
| Corn          | 52.38       | 60.07       | 52.38        | 60.07        |
| Soybean meal, 46.5% CP | 22.00       | 27.88       | 22.00        | 27.88        |
| Casein        | 5.37        | 2.50        | 5.37         | 2.50         |
| Lactose       | 10.00       | 2.50        | 10.00        | 2.50         |
| Fish meal     | 5.00        | 2.50        | 5.00         | 2.50         |
| Soybean oil   | 1.77        | 1.57        | 1.77         | 1.57         |
| L-lysine HCl  | 0.29        | 0.19        | 0.29         | 0.19         |
| DL-methionine | 0.13        | 0.06        | 0.13         | 0.06         |
| L-threonine   | 0.11        | 0.04        | 0.11         | 0.04         |
| L-valine      | 0.20        | 0.00        | 0.20         | 0.00         |
| Monocalcium phosphate, 21% | 1.03 | 0.86 | 1.03 | 0.86 |
| Limestone     | 0.82        | 0.93        | 0.82         | 0.93         |
| Salt          | 0.50        | 0.50        | 0.50         | 0.50         |
| Vitamin premix | 0.25        | 0.25        | 0.25         | 0.25         |
| Mineral premix | 0.15        | 0.15        | 0.15         | 0.15         |
| Chlortetracycline, active ingredient | — | — | 0.04 | 0.04 |

Calculated composition

- CP, % 23.07 21.98 23.07 21.98
- ME, kcal/kg 3,410 3,388 3,410 3,388
- NE, kcal/kg 2,519 2,453 2,519 2,453
- Lys, SID % 1.50 1.29 1.50 1.29

1 Provided per kilogram of diet: 6,125 IU vitamin A, 700 IU vitamin D₃, 50 IU vitamin E, 30 mg vitamin K, 0.05 mg vitamin B₁₂, 11 mg riboflavin, 56 mg niacin, and 27 mg pantothenic acid.
2 Provided per kilogram of diet: 22 mg Cu (as CuSO₄), 220 mg Fe (as FeSO₄), 0.4 mg I (as Ca(IO₃)₂), 52 mg Mn (as MnSO₄), 220 mg Zn (as ZnSO₄), and 0.4 mg Se (as Na₂SeO₃).
3 SID = standardized ileal digestibility

https://doi.org/10.1371/journal.pone.0216070.t001
bolt followed by exsanguination and tissues were collected for analysis. Immediately following euthanasia, sections from the ileum and colon were flushed of luminal contents with Krebs-Henseleit buffer (KH; 25 mM NaHCO$_3$, 120 mM NaCl, 1 mM MgSO$_4$, 6.3 mM KCl, 2 mM CaCl$_2$, and 0.32 mM NaH$_2$PO$_4$, pH 7.4) and placed into aerated bottles containing KB for transportation and mounting into modified Ussing chambers (Physiological Instruments and VCC MC8; World Precisions Instruments, New Haven, CT). Additionally, sections from the ileum, colon, Longissimus dorsi muscle (LM), and liver as well as contents from the cecum were frozen in liquid nitrogen and stored at -80°C until analysis.

**Intestinal integrity and function.** Fresh ileum and colon segments were mounted into modified Ussing chambers (Physiological Instruments, San Diego, CA and World Precision Instruments, Sarasota, FL) to determine intestinal barrier integrity and ileal active nutrient transport. Tissues were pinned and placed vertically into chambers, connected to dual channel voltage and current electrodes submerged in 3% noble agar, and filled with 3 M KCl to provide electrical conductance. The serosal and mucosal sides were bathed in 4 mL KB. Tissue segments were provided with a constant O$_2$-CO$_2$ mixture. Each segment was clamped at a voltage of 0 mV after correction for solution resistance. A pulse current was applied and transepithelial electrical resistance (TER) measurements were calculated based on measured voltage and the change in short circuit current when the current pulse was applied. The TER was averaged over 10 a minute collection period after 10 minutes of stabilization. After 30 and 45 minutes, ileal tissues were independently challenged with the mucosal addition of 10 mM D-glucose and 10 mM L-glutamine, respectively [15]. Equimolar (10 mM) mannitol was concurrently added to the serosal chamber with each challenge. The maximal current was recorded after each challenge, subtracted from the current immediately prior each challenge, and the change in short circuit current (μA) was calculated.

**Cecal short chain fatty acid concentrations**

To evaluate short chain fatty acid (SCFA) concentrations, 1 g of frozen cecal contents were suspended in 2 mL phosphate buffered saline, vortexed for one minute, and debris was pelleted by centrifugation at 5000 × g for 10 minutes. The resulting supernatant (1 mL) was added to heptanoic acid internal standards. Butylated fatty acid esters were generated as described [16], analyzed using an Agilent 7890 GC (Agilent, Santa Clara, CA), and data were reported as a concentration of short chain fatty acid (mM) per gram of cecal content.

**Ileum mRNA abundance**

Total RNA was extracted from frozen ileum samples utilizing the Trizol protocol (Invitrogen, Grand Island, NY). Quantity and purity of extracted RNA was determined using a NanoDrop 1000 (NanoDrop Technologies, Rockland, DE). All samples had a 260/280 ratio of at least 1.8. One microgram of extracted RNA was transcribed using a commercially available kit (Quantitect reverse transcription kit; Qiagen Inc., Valencia, CA) and resulting cDNA was quantified using a Nanodrop 1000 and utilized for quantitative real-time PCR (qPCR) using a BioMark HD system (Fluidigm Corporation, San Francisco, CA). Complementary DNA was amplified using the TaqMan PreAmp Master Mix (Life Technologies, Carlsbad, CA) and loaded onto Fluidigm’s Dynamic Array Integrated Fluidic Circuits following Fluidigm’s EvaGreen DNA binding dye protocol. Gene symbols and primer sequences are listed in S1 Table. The endogenous reference genes RPL32, ACTB, and TOP2B were included in the array for standardization. The mRNA abundance values for each sample were normalized to reference genes and CON pigs according to the 2$^{-\Delta\Delta Ct}$ method.
Proteomics (liquid chromatography–mass spectrometry)

To evaluate tissue protein abundance changes that may occur due to sCTC supplementation, the proteomes of the ileum, colon, LM, and liver were evaluated at 35 days post-weaning. Proteins were analyzed at the Iowa State University Protein Facility (Ames, IA) using a Q-Exactive Hybrid Quadrupole-Orbitrap Mass Spectrometer (ThermoFisher Scientific, Waltham, MA). Proteins were extracted from frozen tissue and digested in trypsin/Lys-C. After digestion, 250 fmol of peptide retention time calibration (PRTC) standard (ThermoFisher Scientific, Waltham, MA) was spiked into each sample as an internal control. Peptides were separated by liquid chromatography and analyzed via MS/MS by fragmentation of peptides. The intact and fragmentation pattern was compared to a theoretical fragmentation pattern using Mascot software (Matrix Science, Boston, MA) to find peptides that were used to identify the proteins against the *Sus scrofa* Swiss-Prot database. Sequest HT software was utilized to run samples against the PRTC database. Label-free quantification, using Minora Feature Detector, was used to detect and quantify isotopic clusters. The PRTC areas were used to normalize data between samples. Identified proteins were sorted by Mascot score, and any protein with a Mascot score < 100 was removed from analysis. Abundances were tabulated after calculating the log₂ change in sCTC pig proteins compared with CON proteins.

Statistical analysis

Statistical analysis was performed in SAS 9.4 (SAS Institute Inc., Cary, NC). Pig performance, intestinal TER, active transport of glucose and glutamine, cecum VFA concentrations production, and Fluidigm data were analyzed using the MIXED procedure to examine dietary treatment effects. The model included a random effect of replicate. Growth performance parameters (ADG, ADFI, and G:F) were analyzed as time repeated measures over the duration of the study.

Protein abundances were quantified via label-free techniques. Statistical significance between treatments was calculated utilizing a Student’s 2-tailed *t*-test. All data are reported as LSmeans and a pooled standard error of the mean (SEM). Significance was determined when *P* < 0.05 and a tendency when 0.05 < *P* < 0.10.

Results

Growth performance

Supplementation of sCTC at a rate of 40 ppm increased (*P* = 0.001, Table 2) ADG by 26% compared with pigs fed the CON diet. As such, sCTC pigs were 4 kg heavier (*P* = 0.002) than CON pigs at 35 days post weaning. This increase in ADG appeared to be primarily feed intake driven, as sCTC pigs had 28% greater (*P* = 0.002) ADFI compared with CON pigs, and G:F did not differ (*P* > 0.10) between treatments. These changes associated with sCTC were observed in both dietary phases.

Intestinal permeability, nutrient uptake, microbial fermentation, and gene abundance

Ileum and colon TERs and ileum active nutrient transport did not differ (*P* > 0.10) between treatments (Table 3). Additionally, cecal SCFA concentrations did not differ (*P* > 0.10) between treatments for either individual or total SCFA (Table 4).

The abundance of the antimicrobial peptide β-defensin 2 (BD2) tended to be reduced (43%, *P* = 0.060) in sCTC pigs compared with CON pigs. Caspase-6 (CASP6), a proteolytic protein, was of 45% greater (*P* = 0.030) abundance in sCTC pigs compared with CON pigs.
The abundance of cytokine chemokine ligand 2 (CCL2) tended to be reduced ($P = 0.074$) in sCTC pigs compared with CON pigs. Additionally, the abundance of anti-inflammatory cytokine interleukin (IL)-10 tended to be reduced ($P = 0.064$) in sCTC pigs compared with CON pigs. However, the abundance of all other genes measured in the ileum did not differ ($P > 0.10$) between treatments.

Protein profile

The protein profiles of the ileum, colon, LM, and liver were evaluated as a shotgun approach to examine proteins and pathways that may be up- or down-regulated due to sCTC supplementation. Of the proteins identified across all tissues examined, 65 protein abundances were significantly different ($P < 0.05$) between sCTC and CON pigs (Table 6). In the ileum, 2 proteins were of lower abundance and 6 proteins were of greater abundance in sCTC pigs.
compared with CON pigs. These proteins were primarily involved with biological processes including metabolism and transport (Fig 2).

In the colon, 23 proteins were of decreased abundance and 2 were of greater abundance in sCTC pigs compared with CON pigs (Table 6). Proteins of decreased abundance, while although having highly varied biological functions, were again primarily involved with metabolism and transport (Fig 2). Proteins of decreased abundance included ADP/ATP translocase 3, several subunits of cytochrome c oxidase, and malate dehydrogenase.

In the LM, 2 proteins were of decreased abundance in sCTC pigs compared with CON pigs (Table 6). These proteins, elongation factor 1-gamma and malate dehydrogenase, were both involved with metabolic processes (Fig 2).

In the liver, 30 proteins were of greater abundance in sCTC pigs compared with CON pigs (Table 6). These proteins were involved with metabolism, regulation of biological processes, response to stimulus, and transport (Fig 2). Many of these proteins were ribosomal proteins, and several proteins involved with energy generation were of increased abundance. The most differentially abundant liver protein was metallothionein-2A, a metal binding protein that had a log$_2$ change of 1.17.

### Discussion

Sub-therapeutic levels of tetracyclines have been widely used in animal agriculture, largely due to their ability to consistently improve growth performance [2]. In the current study, ADG was improved 26% by sCTC (40 ppm), which is a larger increase than what is typically observed in a research setting [17–19]. Interestingly, feed efficiency did not differ in the current study, which differs from much of the historical literature demonstrating that antibiotics improve feed efficiency [19]. However, much of this historical research demonstrating feed efficiency differences is rather old or uses therapeutic doses of antibiotics. The lack of feed efficiency improvement is consistent with more recent observations by Shen et al. [18] using sub-therapeutic CTC. Thus, the lack of feed efficiency differences in the current experiment may

| Parameter                  | CON$^1$ | sCTC$^1$ | SEM  | P-value |
|----------------------------|---------|----------|------|---------|
| Acetate                    | 76.0    | 80.3     | 6.892| 0.547   |
| Butyrate                   | 15.4    | 13.1     | 2.139| 0.465   |
| Caproate                   | 0.07    | 0.12     | 0.047| 0.469   |
| Formate                    | 0.61    | 1.11     | 0.330| 0.297   |
| Isobutyrate                | 0.56    | 0.36     | 0.130| 0.293   |
| Isovalerate                | 0.58    | 0.43     | 0.129| 0.444   |
| Lactate                    | 0.03    | 0.75     | 0.367| 0.196   |
| Oxalate                    | 0.33    | 0.27     | 0.103| 0.665   |
| Phenylacetate              | 0.14    | 0.08     | 0.051| 0.477   |
| Propionate                 | 39.2    | 34.2     | 2.336| 0.158   |
| Succinate                  | 0.43    | 0.46     | 0.086| 0.810   |
| Valerate                   | 2.85    | 2.29     | 0.820| 0.641   |
| Branch chain fatty acids   | 1.14    | 0.79     | 0.253| 0.348   |
| Total SCFA$^2$             | 136.2   | 133.5    | 8.015| 0.812   |

$^1$Mean values are pig estimates (n = 6 pigs/trt)

$^2$SCFA = short chain fatty acid

https://doi.org/10.1371/journal.pone.0216070.t004
be due to more modern pig genetics, more sanitary housing conditions, or the dose of CTC utilized. Further, sCTC pigs were 4 kg heavier than CON pigs at the end of the study, re-emphasizing the impact sub-therapeutic levels of antibiotics can have on nursery pig growth performance and producer economic returns. However, due to consumer and government concerns regarding increasing antimicrobial resistance, AGPs are being phased out of use by production animal agriculture [3, 20]. With the loss of such a crucial production tool, the swine industry has raced to develop alternatives that mimic the growth promoting benefits of AGPs without the risk of increasing antimicrobial resistance. However, despite their heavy usage by the industry for over 50 years, the mode of action by which AGPs improve growth performance is still unclear. Most research that has investigated the impact of CTC on pig growth, metabolism, and microbiota has utilized a therapeutic dose of 400 ppm or greater [21–23], which is 10 times greater than the sub-therapeutic dose used in the industry and likely has different effects on the pig and intestinal microbiota. Thus, this experiment aimed to investigate the mode of sub-therapeutic, rather than therapeutic, concentrations of CTC on pig growth and metabolism.

Table 5. Gene abundance in the ileum of pigs in either control (CON) or sub-therapeutic chlortetracycline (sCTC; 40 ppm) treatments.

| Parameter | CON^1 | sCTC^1 | SEM | P-value |
|-----------|-------|--------|-----|---------|
| BD2       | 0.87  | 0.50   | 0.505 | 0.060   |
| CASP3     | 2.42  | 3.14   | 1.766 | 0.350   |
| CASP6     | 1.11  | 2.03   | 0.270 | 0.030   |
| CCL2      | 1.06  | 0.73   | 0.123 | 0.074   |
| CLDN2     | 1.15  | 1.02   | 1.707 | 0.823   |
| CLDN3     | 1.93  | 2.52   | 0.900 | 0.639   |
| CLDN4     | 2.11  | 2.14   | 1.551 | 0.961   |
| DEFB1     | 0.62  | 0.86   | 0.175 | 0.319   |
| FABP1     | 3.22  | 4.54   | 1.524 | 0.553   |
| IAP       | 5.60  | 4.89   | 3.328 | 0.639   |
| IL10      | 0.92  | 0.56   | 0.138 | 0.064   |
| IL18      | 0.50  | 0.57   | 0.499 | 0.760   |
| IL8       | 1.25  | 0.94   | 0.285 | 0.453   |
| MUC2      | 1.51  | 1.69   | 0.857 | 0.645   |
| NFKB1     | 1.12  | 1.02   | 0.143 | 0.633   |
| OCLN      | 2.28  | 2.42   | 1.387 | 0.812   |
| RELA      | 1.78  | 1.96   | 0.226 | 0.213   |
| SLC5A1    | 4.06  | 4.41   | 2.094 | 0.719   |
| SLC5A8    | 2.62  | 2.85   | 1.561 | 0.907   |
| SLCA2     | 1.54  | 2.12   | 1.377 | 0.314   |
| TFF2      | 1.18  | 1.04   | 0.434 | 0.491   |
| TGFBI     | 0.98  | 0.13   | 0.134 | 0.119   |
| TLR2      | 0.96  | 0.99   | 0.612 | 0.920   |
| TLR3      | 1.22  | 1.15   | 0.361 | 0.895   |
| TLR4      | 0.60  | 0.55   | 0.132 | 0.780   |
| TNFA      | 1.05  | 0.84   | 0.879 | 0.497   |

^1Mean values are pig estimates (n = 6–8 pigs/trt)

^2Gene abundances expressed as fold changes from CON average (2^{\Delta\Delta Ct})

https://doi.org/10.1371/journal.pone.0216070.t005
It has been hypothesized that the improvement in growth observed by feeding AGPs such as sCTC occurs via modulating the microbiome of the host [11], although studies examining microbial changes due to sub-therapeutic antibiotic supplementation have inconsistent results [24–28]. Furthermore, most of these studies failed to report growth performance parameters, making it difficult to evaluate whether changes in microbial communities translate into improved growth performance and/or feed efficiency. In the current experiment, we examined cecal SCFA concentrations as a marker of microbial metabolism, as they are the major products of microbial fermentation [29]. We observed no differences in cecum SCFA concentrations. These data are supported by Shen et al. [18], who observed no changes in SCFA concentrations in the cecum, as well as the colon and rectum of pigs when fed 80 ppm sCTC. This may suggest cecal microbial metabolism is not affected by sCTC and likely not a large contributor to sCTC’s mode of action in augmenting nursery pig growth. However, CTC at 100 ppm has been shown to decrease fecal Bacteroidetes and increase Escherichia and Shigella microbial communities in growing pigs [30]. Additionally, 50 ppm CTC has been shown to shift microbial communities in the ileum of pigs, but growth performance was not presented.
| Description                                                | UniProt ID | Log₂ (CTC/CON) | P-value |
|------------------------------------------------------------|------------|----------------|---------|
| **Ileum**                                                  |            |                |         |
| Cofilin-2                                                  | Q5G6V9     | -1.225         | 0.019   |
| Ubiquitin-conjugating enzyme E2 D2                        | Q06AA9     | -0.744         | 0.030   |
| Arachidonate 15-lipoxygenase                              | P16469     | 1.721          | 0.012   |
| Dolichyl-diphosphooligosaccharide-protein glycosyltransferase subunit 1 | Q9GMB0     | 0.833          | 0.039   |
| Dystrophin                                                 | Q5GN48     | 0.383          | 0.035   |
| Ras-related protein Rab-14                                | Q52NJ6     | 0.567          | 0.012   |
| Sodium/glucose cotransporter 1 (Fragment)                 | P26429     | 1.466          | 0.017   |
| Sodium/potassium-transporting ATPase subunit alpha-2      | D2WKD8     | 0.693          | 0.035   |
| **Colon**                                                  |            |                |         |
| 60S ribosomal protein L15 (Fragment)                      | P79324     | -0.793         | 0.017   |
| 60S ribosomal protein L6                                   | Q2YGT9     | -0.973         | 0.021   |
| 6-phosphogluconate dehydrogenase, decarboxylating (Fragment) | P14332     | -0.977         | 0.024   |
| ADP/ATP translocase 3                                     | Q6QRN9     | -1.149         | 0.018   |
| Aspartate aminotransferase, mitochondrial                  | P00506     | -0.771         | 0.012   |
| Citrate synthase, mitochondrial                           | P00889     | -0.568         | 0.043   |
| Coatomer subunit beta                                     | D2SW95     | -0.846         | 0.048   |
| Cytochrome C oxidase subunit 2                            | P50667     | -1.249         | 0.023   |
| Cytochrome C oxidase subunit 4 isoform 1, mitochondrial (Fragment) | Q95283     | -0.875         | 0.048   |
| Dolichyl-diphosphooligosaccharide-protein glycosyltransferase subunit 2 | Q9GL01     | -0.938         | 0.031   |
| Epithelial cell adhesion molecule                         | Q75QW1     | -0.725         | 0.027   |
| Malate dehydrogenase, cytoplasmic                         | P11708     | -0.607         | 0.045   |
| Microsomal glutathione S-transferase 1                    | P79382     | -1.181         | 0.036   |
| Myosin-11 (Fragments)                                     | P81271     | -0.737         | 0.045   |
| NADH-cytochrome b5 reductase 3 (Fragment)                 | P83686     | -0.905         | 0.039   |
| Prophenin-2                                                | P51525     | -1.676         | 0.037   |
| Ras-related protein Rab-5A                                | Q66A06     | -0.815         | 0.021   |
| Serum albumin                                             | P08835     | -0.641         | 0.021   |
| Signal transducer and activator of transcription 1        | Q764M5     | -0.684         | 0.025   |
| Tubulin alpha-1B chain                                    | Q2XVP4     | -0.607         | 0.036   |
| Voltage-dependent anion-selective channel protein 2       | Q9M1Z5     | -0.833         | 0.045   |
| ATP synthase subunit f, mitochondrial                     | Q95339     | -0.960         | 0.045   |
| Ras-related protein Rab-14                                | Q52NJ6     | -0.966         | 0.045   |
| Phostensin                                                 | Q767M0     | 1.124          | 0.043   |
| Short-chain specific acyl-CoA dehydrogenase, mitochondrial | P79273     | 0.564          | 0.041   |
| **Longissimus muscle**                                    |            |                |         |
| Elongation factor 1-gamma (Fragment)                      | Q29387     | -0.793         | 0.001   |
| Malate dehydrogenase, cytoplasmic                         | P11708     | -0.458         | 0.049   |
| **Liver**                                                  |            |                |         |
| 40S ribosomal protein S12                                 | P46405     | 0.251          | 0.025   |
| 40S ribosomal protein S20                                 | A1XQ99     | 0.314          | 0.003   |
| 40S ribosomal protein S3                                  | Q0Z8U2     | 0.302          | 0.033   |
| 40S ribosomal protein S4                                  | Q4GWZ2     | 0.230          | 0.031   |
| 60S ribosomal protein L11                                 | Q29205     | 0.243          | 0.039   |
| 60S ribosomal protein L29                                 | Q95281     | 0.397          | 0.021   |

(Continued)
Although sub-therapeutic CTC has been shown to modulate bacterial populations, most of these studies have failed to report augmented growth performance. Thus, the role these microbial shifts may play in modulating host intestinal function and integrity, as well as whole-body metabolism and growth, remains unclear.

An alternative, host-centric hypothesis regarding how sub-therapeutic antibiotics facilitate growth has also been proposed [31]. Although this hypothesis has received less attention, it is thought that AGPs act on the host via immunomodulation, decreasing the costs of supporting immune functions and allowing more nutrients to be allocated towards lean tissue accretion and growth [13, 31]. It is also hypothesized that growth promoting antibiotics may result in thinner villi lamina propria, which may allow for enhanced nutrient uptake into the bloodstream [2, 11, 32]. In order to examine if changes in the intestinal barrier are one of the mechanisms by which AGPs improve growth, we utilized modified Ussing Chambers to examine ex vivo intestinal barrier permeability and active nutrient transport in the ileum and colon.

Increases in barrier permeability are associated with periods of inflammation, stress, and a reduction in the capacity for growth [33]. On the contrary, increases in active transport or transporter abundance are associated with the uptake of more nutrients from the intestinal lumen, increasing capacity for growth. In the current experiment, sCTC treatment did not appear to have an impact on small or large intestinal integrity, as assessed by ileum and colon TERs. Similarly, the active transport of glucose and glutamine across the ileum was not different between sCTC and CON pigs. Furthermore, no differences in tight junction protein and nutrient transporter gene abundance were reported. Thus, it appears unlikely that changes to intestinal barrier permeability and active nutrient transport function explained the increased

| Description | UniProt ID | Log2 (CTC/CON) | P-value |
|-------------|-----------|----------------|---------|
| 60S ribosomal protein L32 | Q6QAT0 | 0.301 | 0.004 |
| Apolipoprotein A-1 | P18648 | 0.318 | 0.038 |
| Bifunctional epoxide hydrolase 2 | Q6Q2C2 | 0.437 | 0.046 |
| Cystathionine gamma-lyase | Q19QT7 | 0.341 | 0.029 |
| Cytochrome c oxidase subunit 5B, mitochondrial | Q55G4 | 0.389 | 0.023 |
| Dihydropteridine reductase | Q8MJ30 | 0.308 | 0.022 |
| Elongation factor 1-beta | P29412 | 0.303 | 0.039 |
| Elongation factor 1-gamma (Fragment) | Q29387 | 0.324 | 0.005 |
| Fructose-1,6-bisphosphatase 1 | P06636 | 0.331 | 0.023 |
| Gelsolin (Fragment) | P20305 | 0.853 | 0.002 |
| Glucose-6-phosphate isomerase | P08059 | 0.312 | 0.018 |
| Hemoglobin subunit alpha | P01965 | 0.555 | 0.046 |
| Hemoglobin subunit beta | P02067 | 0.651 | 0.028 |
| Hemopexin | P05828 | 0.609 | 0.016 |
| High mobility group protein B1 | P12682 | 0.502 | 0.017 |
| High mobility group protein B2 | P17741 | 0.557 | 0.048 |
| Metallothionein-2A | P79379 | 1.170 | 0.012 |
| Peroxiredoxin-2 (Fragment) | P52552 | 0.197 | 0.042 |
| Prelamin-A/C | Q3ZD69 | 0.358 | 0.013 |
| Serine/threonine-protein phosphatase 2A 65 kDa regulatory subunit A beta isoform (Fragment) | P54613 | 0.330 | 0.034 |
| Serotransferrin | P09571 | 0.505 | 0.028 |
| Serum albumin | P08835 | 0.455 | 0.011 |
| Thymosin beta-4 | Q95274 | 0.780 | 0.010 |
| Transitional endoplasmic reticulum ATPase | P03974 | 0.192 | 0.021 |

https://doi.org/10.1371/journal.pone.0216070.t006
growth associated with sCTC treatments. However, it is noted these measurements were only collected at the end the study, and any changes in these parameters may have stabilized by the end of the 35 day trial.

In line with the immunomodulatory hypothesis, the abundance of the antimicrobial peptide BD2 tended to be reduced in sCTC pigs compared with CON pigs. Beta-defensin 2 has been shown to have antimicrobial activity in the intestine [34] and likely possesses pro-
inflammatory and chemoattractant effects [35], thus a reduction in BD2 may suggest a lower level of inflammation at the ileal epithelium. Similarly, the chemoattractant CCL2 had reduced abundance in sCTC pigs, suggesting that AGPs may act to reduce inflammation at the ileum. These localized reductions in inflammation may translate into a global reduction in inflammatory markers, which has been observed in the serum of pigs treated with sub-therapeutic oxy-tetracycline [36]. Reductions in circulating inflammatory markers such as cytokines, which are known to reduce appetite [37], may help explain the increased feed intake and thus increased growth of sCTC pigs.

Several more important findings from this study are that the proteomes of the ileum, colon, skeletal muscle, and liver were all found to be altered by sCTC addition to the diet. Further, protein changes were tissue specific, but consistently involved with metabolism. Interestingly, differentially abundant proteins showed a clear trend towards downregulation in the colon, and a clear trend towards upregulation in the liver. Only 2 proteins were differentially abundant in the LM, suggesting that LM metabolism is largely unaffected by sCTC. Downregulated proteins in the colon were largely related to metabolism and transport, such as ADP/ATP translocase, malate dehydrogenase, and electron transport chain components cytochrome c oxidase subunit 2 and subunit 4. This suggests that the colon is less metabolically active in pigs fed sCTC, perhaps reflecting a large intestinal energy sparing mechanism. Metabolism related proteins in the liver were of greater abundance, such as the glycolytic protein glucose-6-phosphate isomerase, the gluconeogenic enzyme fructose-1,6-bisphosphatase, and cytochrome c oxidase. Additionally, elongation factors 1-beta and 1-gamma, proteins that facilitate translation elongation, were also of greater abundance in the liver. The liver is a highly metabolic organ in the pig [38], thus an increase in metabolism related proteins is unsurprising, and likely related to the overall faster growth rate of the sCTC pigs. An upregulation in genes related to lipogenesis and triglyceride synthesis have been observed in the liver of mice dosed with sub-therapeutic levels of various antibiotics, including penicillin and chlortetracycline [39], demonstrating that sub-therapeutic antibiotics directly modulate the host and furthers the hypothesis that the growth promoting characteristics of AGPs are partially a result of the host response. However, these changes in metabolism and growth may also just be a function of higher feed intakes, which we and others [17, 18] have observed to be increased as a result of sCTC supplementation.

In conclusion, in-feed sub-therapeutic CTC supplementation at 40 ppm increased nursery pig growth performance, primarily due to an increase in feed intake. Ileum integrity and function, and cecal microbial metabolism do not appear to explain the differences observed. However, changes in several ileum transcripts suggest that inflammation may be reduced in sCTC pigs. Further, the changes seen in the proteomic profile suggest that the sub-therapeutic mode of action of AGPs may include post-absorptive changes and warrants further investigation.

Supporting information

S1 Table. Primer sequences.
(DOCX)

S1 Dataset. Raw data files.
(ZIP)

Acknowledgments

The authors thank Joel Nott and Steven Lonergan their technical assistance and Trey Faaborg for help with diet mixing and pig care.
Author Contributions
Conceptualization: Nicholas K. Gabler.
Data curation: Emma T. Helm.
Formal analysis: Emma T. Helm, Shelby Curry, Martine Schroyen, Nicholas K. Gabler.
Funding acquisition: Nicholas K. Gabler.
Investigation: Emma T. Helm, Shelby Curry, Julian M. Trachsel, Martine Schroyen, Nicholas K. Gabler.
Methodology: Emma T. Helm, Shelby Curry, Julian M. Trachsel, Martine Schroyen, Nicholas K. Gabler.
Supervision: Martine Schroyen, Nicholas K. Gabler.
Writing – original draft: Emma T. Helm, Nicholas K. Gabler.
Writing – review & editing: Emma T. Helm, Shelby Curry, Julian M. Trachsel, Martine Schroyen, Nicholas K. Gabler.

References

1. Moore PR, Evenson A, Luckey TD, Mccoy E, Elvehjem CA, Hart EB. Use of Sulfasuxidine, Streptomycin, and Streptomycin in Nutritional Studies with the Chick. J Biol Chem. 1946; 165(2):437–41. PMID: 20276107
2. Gaskins HR, Collier CT, Anderson DB. Antibiotics as growth promotants: mode of action. Anim Biotechnol. 2002; 13(1):29–42. https://doi.org/10.1081/ABIO-120005768 PMID: 12212942
3. FDA. The judicious use of medically important antimicrobial drugs in food-producing animals. Rockville, MD: Food and Drug Administration; 2012.
4. Wallace HD. Biological responses to antibacterial feed additives in diets of meat producing animals. J Anim Sci. 1970; 31(6):1118–26. PMID: 4926472
5. Rushton J. Anti-microbial Use in Animals: How to Assess the Trade-offs—Rushton—2015—Zoonoses and Public Health—Wiley Online Library. Zoonoses and Public Health. 2015(2015 suppl 1):10–21. https://doi.org/10.1111/zph.12198 PMID: 25917650
6. Griffin MO, Ceballos G, Villarreal FJ. Tetracycline compounds with non-antimicrobial organ protective properties: possible mechanisms of action. Pharmaco Res. 2011; 63(2):102–7. https://doi.org/10.1016/j.phrs.2010.10.004 PMID: 20951211
7. Petkovic H, Lukezic T, Suskovic J. Biosynthesis of Oxytetracycline by Streptomycetes rimosus: Past, Present and Future Directions in the Development of Tetracycline Antibiotics. Food Technol Biotechnol. 2017; 55(1):3–13. https://doi.org/10.17113/ftb.55.01.17.4617 PMID: 28559729
8. FDA. Chlorotetraycline Breeding Swine Feed FDA2018 [Available from: https://www.fda.gov/downloads/AnimalVeterinary/Products/AnimalFoodFeeds/MedicatedFeed/BlueBirdLabels/UCM368164.pdf.
9. Brown K, Uwiera RRE, Kalmokoff ML, Brooks SPJ, Inglis GD. Antimicrobial growth promoter use in livestock: a requirement to understand their modes of action to develop effective alternatives. Int J Antimicrob Agents. 2017; 49(1):12–24. https://doi.org/10.1016/j.ijantimicag.2016.08.006 PMID: 27717740
10. Flynn WT. Guidance for Industry #209: The Judicious Use of Medically Important Antimicrobial Drugs in Food-Producing Animals. In: Services USDaH, editor. Food and Drug Administration, Center for Veterinary Medicine2012.
11. Dibner JJ, Richards JD. Antibiotic growth promoters in agriculture: history and mode of action. Poult Sci. 2005; 84(4):634–43. https://doi.org/10.1093/ps/84.4.634 PMID: 15844822
12. Coates ME, Fuller R, Harrison G, Lev M, Suffolk S. A comparison of the growth of chicks in the Gustafsson germ-free apparatus and in a conventional environment, with and without dietary supplements of penicillin. Br J Nutr. 1963; 17(1):141–50.
13. Costa E, Uwiera RR, Kastelic JP, Selinger LB, Inglis GD. Non-therapeutic administration of a model antimicrobial growth promoter modulates intestinal immune responses. Gut Pathog. 2011; 3(1):14. https://doi.org/10.1186/1757-4749-3-14 PMID: 21943280
14. National Research Council. Nutrient requirements of swine: Eleventh revised edition. Washington, DC: The National Academies Press; 2012.

15. Gabler NK, Spencer JD, Webel DM, Spurlock ME. In utero and postnatal exposure to long chain (n-3) PUFA enhances intestinal glucose absorption and energy stores in weanling pigs. J Nutr. 2007; 137 (11):2351–8. https://doi.org/10.1093/jn/137.11.2351 PMID: 17951469

16. Salanitro JP, Muirhead PA. Quantitative Method for the Gas Chromatographic Analysis of Short-Chain Monocarboxylic and Dicarboxylic Acids in Fermentation Media. Applied Microbiology. 1975; 29(3):374–81. PMID: 1167776

17. Liu P, Piao XS, Kim SW, Wang L, Shen YB, Lee HS, et al. Effects of chito-oligosaccharide supplementation on the growth performance, nutrient digestibility, intestinal morphology, and fecal shedding of Escherichia coli and Lactobacillus in weaning pigs. J Anim Sci. 2008; 86(10):2609–18. https://doi.org/10.2527/jas.2007-0668 PMID: 18502883

18. Shen YB, Piao XS, Kim SW, Wang L, Liu P, Yoon I, et al. Effects of yeast culture supplementation on growth performance, intestinal health, and immune response of nursery pigs. J Anim Sci. 2009; 87 (8):2614–24. https://doi.org/10.2527/jas.2008-1512 PMID: 19395514

19. Cromwell GL. Why and how antibiotics are used in swine production. Anim Biotechnol. 2002; 13(1):7–27. https://doi.org/10.1081/ABIO-120005767 PMID: 12212945

20. Casewell M, Friis C, Marco E, McMullin P, Phillips I. The European ban on growth-promoting antibiotics and emerging consequences for human and animal health. J Antimicrob Chemother. 2003; 52(2):159–61. https://doi.org/10.1093/jac/dkg313 PMID: 12837737

21. Levesque CL, Hooda S, Swanson KS, de Lange K. Alterations in Ileal Mucosa Bacteria Related to Diet Complexity and Growth Performance in Young Pigs. PLoS One. 2014; 9(9):e108472. https://doi.org/10.1371/journal.pone.0108472 PMID: 25247930

22. Ipharraguerre IR, Pastor JJ, Gavaldà-Navarro A, Villarroya F, Mereu A. Antimicrobial promotion of pig growth is associated with tissue-specific remodeling of bile acid signature and signaling. Sci Rep. 2018; 8(1):13671. https://doi.org/10.1038/s41598-018-32107-9 PMID: 30209339

23. Williams HE, Woodworth JC, DeRouchey JM, Tokach MD, Goodband RD, Amachawadi RG, et al. Effects of chlortetracycline alone or in combination with direct fed microbials on nursery pig growth performance and antimicrobial resistance of fecal Escherichia coli1. J Anim Sci. 2018; 96(12):5166–78. https://doi.org/10.1093/jas/sky370 PMID: 30358839

24. Unno T, Kim JM, Guevarra RB, Nguyen SG. Effects of antibiotic growth promoter and characterization of ecological succession in Swine gut microbiota. J Microbiol Biotechnol. 2015; 25(4):431–8. PMID: 25370726

25. Collier CT, Smiricky-Tjardes MR, Albin DM, Wubben JE, Gabert VM, Deplancke B, et al. Molecular ecological analysis of porcine ileal microbiota responses to antimicrobial growth promoters. J Anim Sci. 2003; 81(12):3035–45. https://doi.org/10.2527/2003.81123035x PMID: 14677859

26. Rettelde E, Vilain S, Lindblom S, Lehner K, Scofield C, George S, et al. Alteration of the ileal microbiota of weanling piglets by the growth-promoting antibiotic chlortetracycline. Appl Environ Microbiol. 2009; 75(17):5489–95. https://doi.org/10.1128/AEM.02220-08 PMID: 1967391

27. Kim HB, Borewicz K, White BA, Singer RS, Sreevatsan S, Tu ZJ, et al. Microbial shifts in the swine distal gut in response to the treatment with antimicrobial growth promoter, tylosin. Proc Natl Acad Sci U S A. 2012; 109(38):15485–90. https://doi.org/10.1073/pnas.1205147109 PMID: 22958866

28. Kalmokoff M, Waddington LM, Thomas M, Liang KL, Ma C, Topp E, et al. Continuous feeding of antimicrobial growth promoters to commercial swine during the growing/finishing phase does not modify faecal community erythromycin resistance or community structure. J Appl Microbiol. 2011; 110(6):1414–25. https://doi.org/10.1111/j.1365-2672.2011.04992.x PMID: 21395944

29. Bergman EN. Energy contributions of volatile fatty acids from the gastrointestinal tract in various species. Physiol Rev. 1990; 70(2):567–90. https://doi.org/10.1152/physrev.1990.70.2.567 PMID: 2181501

30. Looft T, Johnson TA, Allen HK, Bayles DO, Alt DP, Stedtfeld RD, et al. In-feed antibiotic effects on the swine intestinal microbiome. Proc Natl Acad Sci U S A. 2012; 109(5):1691–6. https://doi.org/10.1073/pnas.1120238109 PMID: 22307632

31. Niewold TA. The nonantibiotic anti-inflammatory effect of antimicrobial growth promoters, the real mode of action? A hypothesis. Poult Sci. 2007; 86(4):605–9. https://doi.org/10.1093/ps/86.4.605 PMID: 17369528

32. Visek WJ. The Mode of Growth Promotion by Antibiotics. J Anim Sci. 1978; 46(5):1447–69. https://doi.org/10.2527/jas1978.4651447x

33. Moeser AJ, Pohl CS, Rajput M. Weaning stress and gastrointestinal barrier development: Implications for lifelong gut health in pigs. Anim Nutr. 2017; 3(4):313–21. https://doi.org/10.1016/j.aninut.2017.06.003 PMID: 29767141
34. Veldhuizen EJ, Rijnders M, Claassen EA, van Dijk A, Haagsman HP. Porcine beta-defensin 2 displays broad antimicrobial activity against pathogenic intestinal bacteria. Mol Immunol. 2008; 45(2):386–94. https://doi.org/10.1016/j.molimm.2007.06.001 PMID: 17658606

35. Lai Y, Gallo RL. AMPed up immunity: how antimicrobial peptides have multiple roles in immune defense. Trends Immunol. 2009; 30(3):131–41. https://doi.org/10.1016/j.it.2008.12.003 PMID: 19217824

36. Soler L, Miller I, Hummel K, Razzazi-Fazeli E, Jessen F, Escribano D, et al. Growth promotion in pigs by oxytetracycline coincides with down regulation of serum inflammatory parameters and of hibernation-associated protein HP-27. Electrophoresis. 2016; 37(10):1277–86. https://doi.org/10.1002/elps.201500529 PMID: 26914286

37. Johnson RW. Inhibition of growth by pro-inflammatory cytokines: an integrated view. J Anim Sci. 1997; 75(5):1244–55. https://doi.org/10.2527/1997.7551244x PMID: 9159271

38. Jobgen WS, Fried SK, Fu WJ, Meininger CJ, Wu G. Regulatory role for the arginine-nitric oxide pathway in metabolism of energy substrates. J Nutr Biochem. 2006; 17(9):571–88. https://doi.org/10.1016/j.jnutbio.2005.12.001 PMID: 16524713

39. Cho I, Yamanishi S, Cox L, Methe BA, Zavadil J, Li K, et al. Antibiotics in early life alter the murine colonic microbiome and adiposity. Nature. 2012; 488(7413):621–6. https://doi.org/10.1038/nature11400 PMID: 22914093